SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 30 of 83
Word Count: 1419
Character Count: 9189

Document Content:

of publicly held shares, corporate governance and various additional requirements. If we are unable to satisfy Nasdaq criteria for maintaining our listing, our securities could be subject to delisting. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements. Our management will have broad discretion in how we use the net proceeds from this offering and might not use them effectively.

Our
management will have considerable discretion over the use of proceeds from this offering. We currently intend to use the net proceeds
from this offering primarily to fund the RELIVE Trial and the associated manufacturing activities required to support such trial. The
remaining portion of the net proceeds will be used to fund working capital and general administrative expenses. You will not have the
opportunity, as part of your investment decision, to assess whether the proceeds are being used in a manner which you may consider most
appropriate. Our management might spend a portion or all of the net proceeds from this offering in ways that our stockholders do not
desire or that do not necessarily improve our operating results or enhance the value of our common stock. The failure of our management
to apply these proceeds effectively could, among other things, result in unfavorable returns and uncertainty about our prospects, each
of which could cause the price of our common stock to decline.

You
will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.

You
will incur immediate and substantial dilution as a result of this offering. After giving effect to the sale by us of             shares
in this offering at an assumed initial public offering price of $          per share (the
midpoint of the estimated price range set forth on the cover page of this prospectus), and after deducting underwriting discounts and
estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of $         per
share at the assumed initial public offering price. Additionally, to the extent that warrants (including the Representative’s
Warrant), or options we will grant to our officers, directors and employees, are ultimately exercised, you will sustain future dilution.
We may also acquire new businesses or finance strategic alliances by issuing equity, which may result in additional dilution to our stockholders.
Following the completion of this offering, our board of directors has the authority, within any limitations prescribed by relevant laws
and our charter documents, to issue all or any part of our authorized but unissued shares of common stock, including shares issuable
upon the exercise of options, or shares of our authorized but unissued preferred stock. Issuances of common stock or voting preferred
stock would reduce your influence over matters on which our stockholders vote and, in the case of issuances of preferred stock, would
likely result in your interest in us being subject to the prior rights of holders of that preferred stock. See the section titled “Dilution.”

will incur significant costs as a result of operating as a public company and our management expects to devote substantial time to public
company compliance programs.

a public company, we will incur significant legal, accounting and other expenses due to our compliance with regulations and disclosure
obligations applicable to us, including compliance with the Sarbanes-Oxley Act, as well as rules implemented by the SEC and Nasdaq. Shareholder
activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial
new regulations and disclosure obligations, which may lead to additional compliance costs and impact, in ways we cannot currently anticipate,
the manner in which we operate our business. Our management and other personnel will devote a substantial amount of time to these compliance
programs and monitoring of public company reporting obligations and as a result of the new corporate governance and executive compensation
related rules, regulations and guidelines prompted by the Dodd-Frank Act and further regulations and disclosure obligations expected
in the future, we will likely need to devote additional time and costs to comply with such compliance programs and rules. These rules
and regulations will cause us to incur significant legal and financial compliance costs and will make some activities more time-consuming
and costly.

comply with the requirements of being a public company, we may need to undertake various actions, including implementing new internal
controls and procedures and hiring new accounting or internal audit staff. The Sarbanes-Oxley Act requires that we maintain effective
disclosure controls and procedures and internal control over financial reporting. We are continuing to develop and refine our disclosure
controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file
with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information
required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers.
Our current controls and any new controls that we develop may become inadequate and weaknesses in our internal control over financial
reporting may be discovered in the future. Any failure to develop or maintain effective controls when we become subject to this requirement
could negatively impact the results of periodic management evaluations and annual independent registered public accounting firm attestation
reports regarding the effectiveness of our internal control over financial reporting that we may be required to include in our periodic
reports we will file with the SEC under Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, harm our operating
results, cause us to fail to meet our reporting obligations or result in a restatement of our prior period financial statements. In the
event that we are not able to demonstrate compliance with the Sarbanes-Oxley Act, that our internal control over financial reporting
is perceived as inadequate or that we are unable to produce timely or accurate financial statements, investors may lose confidence in
our operating results and the price of our common stock could decline. In addition, if we are unable to continue to meet these requirements,
we may not be able to remain listed on Nasdaq.

restated certain of our previously issued consolidated financial statements, which resulted in unanticipated costs and may affect investor
confidence and raise reputational issues.

reached a determination to restate our consolidated financial statements and related disclosures for the year ended December 31,
2024 included elsewhere in this prospectus. As a result, we have incurred unanticipated costs for accounting, professional and legal
fees in connection with or related to the restatement, and could become subject to a number of additional risks and uncertainties,
which may affect investor confidence in the accuracy of our financial disclosures and may raise reputational issues for our
business.

Unanticipated
changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect
our financial condition and results of operations.

will be subject to income taxes in the United States, and our domestic tax liabilities will be subject to the allocation of expenses
in differing jurisdictions. Our future effective tax rates could be subject to volatility or adversely affected by a number of factors,
including:

●	changes
in the valuation of our deferred tax assets and liabilities;

●	expected
timing and amount of the release of any tax valuation allowances;

●	tax
effects of stock-based compensation;

●	costs
related to intercompany restructurings; or

●	changes
in tax laws, regulations or interpretations thereof.

addition, we may be subject to audits of our income, sales and other transaction taxes by federal, state and local authorities. Outcomes
from these audits could have an adverse effect on our financial condition and results of operations.

Provisions
in our charter documents and under Delaware law, including anti-takeover provisions, could make an acquisition of us, which may be beneficial
to our stockholders, more difficult and may limit attempts by our stockholders to replace or remove our current management.